$67.54
0.98% today
Nasdaq, Sep 24, 06:17 pm CET
ISIN
US2521311074
Symbol
DXCM

DexCom, Inc. Stock price

$68.20
-7.76 10.22% 1M
-7.12 9.45% 6M
-9.57 12.31% YTD
-1.50 2.15% 1Y
-12.46 15.45% 3Y
-28.32 29.34% 5Y
+43.06 171.31% 10Y
+65.13 2,121.50% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
-1.31 1.88%
ISIN
US2521311074
Symbol
DXCM

Key metrics

Basic
Market capitalization
$26.7b
Enterprise Value
$26.3b
Net debt
positive
Cash
$2.9b
Shares outstanding
392.2m
Valuation (TTM | estimate)
P/E
48.7 | 32.6
P/S
6.2 | 5.7
EV/Sales
6.1 | 5.6
EV/FCF
46.1
P/B
10.4
Financial Health
Equity Ratio
32.4%
Return on Equity
27.4%
ROCE
17.1%
ROIC
12.9%
Debt/Equity
1.0
Financials (TTM | estimate)
Revenue
$4.3b | $4.7b
EBITDA
$923.3m | $1.4b
EBIT
$687.2m | $973.2m
Net Income
$571.5m | $819.7m
Free Cash Flow
$570.8m
Growth (TTM | estimate)
Revenue
9.3% | 17.0%
EBITDA
4.1% | 56.7%
EBIT
0.8% | 48.9%
Net Income
-14.3% | 42.3%
Free Cash Flow
-14.2%
Margin (TTM | estimate)
Gross
60.0%
EBITDA
21.5% | 28.9%
EBIT
16.0%
Net
13.3% | 17.4%
Free Cash Flow
13.3%
More
EPS
$1.4
FCF per Share
$1.5
Short interest
3.6%
Employees
10k
Rev per Employee
$390.0k
Show more

Create a Free Account to create an DexCom, Inc. alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

DexCom, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

35 Analysts have issued a DexCom, Inc. forecast:

30x Buy
86%
5x Hold
14%

Analyst Opinions

35 Analysts have issued a DexCom, Inc. forecast:

Buy
86%
Hold
14%

Financial data from DexCom, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4,301 4,301
9% 9%
100%
- Direct Costs 1,720 1,720
19% 19%
40%
2,581 2,581
4% 4%
60%
- Selling and Administrative Expenses 1,272 1,272
3% 3%
30%
- Research and Development Expense 568 568
4% 4%
13%
923 923
4% 4%
21%
- Depreciation and Amortization 236 236
15% 15%
5%
EBIT (Operating Income) EBIT 687 687
1% 1%
16%
Net Profit 572 572
14% 14%
13%

In millions USD.

Don't miss a Thing! We will send you all news about DexCom, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

DexCom, Inc. Stock News

Negative
The Motley Fool
one day ago
Medical device specialist DexCom (DXCM -0.10%) has encountered significant headwinds since last year. The company's financial results in 2024 weren't nearly as strong as the market had expected, and over the past eight months, it has faced the threat of tariffs that could harm its margins and bottom line.
Neutral
Seeking Alpha
4 days ago
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Neutral
PRNewsWire
5 days ago
NEW YORK , Sept. 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders.
More DexCom, Inc. News

Company Profile

DexCom, Inc. is a medical device manufacturing company. The firm engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, DexCom G5 Mobil, DexCom Share and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Head office United States
CEO Kevin Sayer
Employees 10,250
Founded 1999
Website www.dexcom.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today